Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 7
2004 10
2005 8
2006 10
2007 15
2008 13
2009 4
2010 1
2011 1
2015 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Miyosawa K, Watanabe Y, Murakami K, Murakami T, Shibata H, Iwashita M, Yamazaki H, Yamazaki K, Ohgiya T, Shibuya K, Mizuno K, Tanabe S, Singh SA, Aikawa M. Miyosawa K, et al. Among authors: yamazaki k. Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E177-90. doi: 10.1152/ajpendo.00528.2014. Epub 2015 May 26. Am J Physiol Endocrinol Metab. 2015. PMID: 26015437 Free article.
Clinical investigation of malignant mesothelioma in Japan.
Fujimoto N, Aoe K, Gemba K, Kato K, Yamazaki K, Kishimoto T. Fujimoto N, et al. Among authors: yamazaki k. J Cancer Res Clin Oncol. 2010 Nov;136(11):1755-9. doi: 10.1007/s00432-010-0834-7. Epub 2010 Mar 6. J Cancer Res Clin Oncol. 2010. PMID: 20213099
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T. Morita S, et al. Among authors: yamazaki k. Clin Cancer Res. 2009 Jul 1;15(13):4493-8. doi: 10.1158/1078-0432.CCR-09-0391. Epub 2009 Jun 16. Clin Cancer Res. 2009. PMID: 19531624
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S, Hagiwara K; North East Japan Gefitinib Study Group. Inoue A, et al. Among authors: yamazaki k. J Clin Oncol. 2009 Mar 20;27(9):1394-400. doi: 10.1200/JCO.2008.18.7658. Epub 2009 Feb 17. J Clin Oncol. 2009. PMID: 19224850 Clinical Trial.
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T. Inoue A, et al. Among authors: yamazaki k. J Clin Oncol. 2008 Nov 20;26(33):5401-6. doi: 10.1200/JCO.2008.18.1974. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854562 Clinical Trial.
71 results